Entasis Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Entasis Therapeutics's estimated annual revenue is currently $10.4M per year.
- Entasis Therapeutics's estimated revenue per employee is $546,579
- Entasis Therapeutics's total funding is $199.5M.
Employee Data
- Entasis Therapeutics has 19 Employees.
- Entasis Therapeutics grew their employee count by -46% last year.
Entasis Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.2M | 2 | 0% | N/A | N/A |
#3 | $4.2M | 27 | 8% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $1.4M | 5 | 0% | N/A | N/A |
#6 | $235M | 246 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | N/A | 37 | 76% | N/A | N/A |
#10 | $5.3M | 29 | 4% | N/A | N/A |
What Is Entasis Therapeutics?
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of novel clinical and preclinical antibacterial programs is designed to revolutionize the way physicians treat serious bacterial diseases.
keywords:N/A
$199.5M
Total Funding
19
Number of Employees
$10.4M
Revenue (est)
-46%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Entasis Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Director, API Process Development | Reveal Email/Phone |
2 | Chief Development Officer | Reveal Email/Phone |
3 | Senior Scientist | Reveal Email/Phone |
4 | Sr. Scientist | Reveal Email/Phone |
5 | Associate Director | Reveal Email/Phone |
6 | VP Clinical Development | Reveal Email/Phone |
7 | VP, DMPK | Reveal Email/Phone |
8 | VP, Head Global Regulatory Affairs and Pharmacovigilance Operations | Reveal Email/Phone |
9 | Director, Clinical Scientist | Reveal Email/Phone |
10 | CFO/Chief Business Officer | Reveal Email/Phone |
Entasis Therapeutics News
About Entasis Therapeutics Holdings Inc. Entasis is a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Global Acinetobacter Infections Treatment Market 2022 Valuable Growth Prospects Analysis by 2028 | Entasis Therapeutics, Roche,...
-$0.20 Earnings Per Share Expected for Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) This Quarter. Posted by admin on Apr 13th, 2022.
Entasis Therapeutics, a Waltham, Mass.-based leader in the discovery and development of anti-infective products, closed a $31.9m Series B-1 extension financing. The financing expansion adds Pivotal bioVenture Partners, Sofinnova Ventures and TPG Biotech to the original Series B funding round of ...
Entasis Therapeutics, a Waltham, Mass.-based company focused on the discovery and development of anti-infective products, completed a $50m Series B financing. The round was led by Clarus with participation from Frazier Healthcare Partners, Novo A/S, and Eventide Funds, which joined founding inv ...
Other Companies in Waltham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2M | 19 | -5% | N/A |
#2 | $5.9M | 20 | 5% | N/A |
#3 | $2M | 20 | -13% | $58M |
#4 | $2.6M | 21 | N/A | N/A |
#5 | N/A | 21 | 11% | N/A |